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Universitario Marqués de Valdecilla, Santander, SpainIntroduction: Secondary hyperparathyroidism (SHPT) and vitamin D deficiency are common at kidney
transplantation and are associated with some early and late complications. This study was designed to
evaluate whether paricalcitol was more effective than nutritional vitamin D for controlling SHPT in de novo
kidney allograft recipients.
Methods: This was a 6-month, investigator-initiated, multicenter, open-label, randomized clinical trial.
Patients with pretransplantation iPTH between 250 and 600 pg/ml and calcium <10 mg/dl were random-
ized to paricalcitol (PAR) or calcifediol (CAL). The intention-to-treat population (PAR: n ¼ 46; CAL: n ¼ 47)
was used for the analysis. The primary endpoint was the percentage of patients with serum iPTH >110
pg/ml at 6 months. Secondary endpoints were bone mineral metabolism, renal function, and allograft
protocol biopsies.
Results: The primary outcome occurred in 19.6% of patients in the PAR group and 36.2% of patients in the
CAL group (P ¼ 0.07). However, there was a higher percentage of patients with iPTH <70 pg/ml in the PAR
group than in the CAL group (63.4% vs. 37.2%; P ¼ 0.03). No differences were observed in bone turnover
biomarkers and bone mineral density. The estimated glomerular filtration rate was significantly higher in
the CAL group than in the PAR group without differences in albuminuria. In protocol biopsies, interstitial
fibrosis and tubular atrophy tended to be higher in the PAR group than in the CAL group (48% vs. 23.8%;
P ¼ 0.09). Both medications were well tolerated.
Conclusion: Both PAR and CAL reduced iPTH, but PAR was associated with a higher proportion of patients
with iPTH <70 pg/ml. These results do not support the use of PAR to treat posttransplantation
hyperparathyroidism.
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idney allograft recipients are considered patients
with chronic kidney diseasemineral and bone
disorder (CKD-MBD), including hyperparathyroidismspondence: Josep M. Cruzado, Nephrology Department,
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pitalet de Llobregat, Barcelona 08907, Spain. E-mail:
zado@bellvitgehospital.cat
ved 14 May 2017; revised 23 August 2017; accepted 29
t 2017; published online 8 September 2017and post-transplantation bone disease.1 Immunosup-
pression, severity of hyperparathyroidism, disturbed
vitamin D levels, and the degree of renal function
achieved play a key role in CKD-MBD disturbances
after transplantation. Therefore, various guidelines
recommend exhaustive monitoring of mineral meta-
bolism in patients with transplants.2,3
Secondary hyperparathyroidism (SHPT) is a common
complication in CKD. Although kidney transplantation
rapidly restores the glomerular filtration rate (GFR) andKidney International Reports (2018) 3, 122–132
JM Cruzado et al.: Vitamin D and Transplantation CLINICAL RESEARCHthe renal capacity to respond to parathyroid hormone
(PTH),4,5 in 20% to 30% of cases, parathyroid gland
resistance to inhibitory feedback persists several years
after transplantation.5 Inappropriately high PTH levels
are associated with hypercalcemia, hypophosphatemia,
renal allograft calcifications and dysfunction, loss of
bone mineral density (BMD), an increased risk of
fracture, vascular calcification, and an increased risk of
cardiovascular events.6–9 These conditions are named
tertiary hyperparathyroidism or persistent hyperpara-
thyroidism after kidney transplantation.10
Reduced vitamin D levels are frequent and persist in
being low after kidney transplantation.1 Vitamin D
metabolism can be influenced by allograft dysfunction,
persistent hyperparathyroidism, and elevated fibro-
blast growth factor-23 (FGF23).1 Although FGF23
reduces conversion of 25 to 1,25-(OH)2-D, PTH and
hypophosphatemia11 have the opposite effect and can
increase 1,25(OH)2-D synthesis, which can reduce the
25(OH) levels by increasing its conversion.1 Some
observational studies have investigated the correlation
between vitamin D deficiency and graft outcomes.1,12 It
has been reported that low 25(OH)D levels predict GFR
decline and mortality.13,14 Although international
guidelines recommend replenishment of vitamin D,
there are few studies on vitamin D therapy in renal
transplantation.1 Therefore, there is a lack of recom-
mendations regarding the use of nutritional vitamin D,
active vitamin D, or vitamin D receptor activator
(VDRA).
In CKD patients, a large number of studies
comparing paricalcitol (PAR), a VDRA, versus active
vitamin D (calcitriol) have shown the efficacy of PAR
on reducing intact parathyroid hormone (iPTH) with
a significantly lower risk of hypercalcemia. PAR and
calcitriol, in the CKD population, have been associ-
ated with reduced cardiovascular disease and mor-
tality,15 although patients who received PAR had a
survival advantage over those who received calci-
triol.15,16 PAR also showed antiproteinuric and
nephroprotective effects, based primarily on the
partial inhibition of the renin-angiotensin system, as
well as endothelial protection, and anti-inflammatory
and immunomodulatory properties.17–19
Currently, there are few studies on PAR in trans-
plantation patients. Amer et al.20 demonstrated that
PAR was superior to placebo in reducing 1-year
post-transplantation SHPT, although there were no
differences in BMD, proteinuria, and renal function. In
contrast, in prevalent kidney allograft recipients with
SHPT, Trillini et al.21 showed that PAR reduced iPTH,
attenuated bone remodeling and mineral loss, and
reduced estimated GFR (eGFR) and proteinuria. How-
ever, there is a lack of studies that have compared PARKidney International Reports (2018) 3, 122–132with nutritional vitamin D. Thus, this is the first
clinical trial aimed to evaluate whether PAR is
more effective than calcifediol (CAL) for controlling
post-transplantation hyperparathyroidism in de novo




This was an investigator-initiated, multicenter,
parallel-group, open-label, randomized prospective
clinical trial. The study was promoted by the Spanish
Society of Nephrology and approved by The Spanish
Drug Agency (EudraCT 2013-001326-25) and registered
as Clinical Trial NCT01939977. Study participants were
identified among recipients of kidney transplantations
ages 18 years or older with SHPT who at the baseline
evaluation fulfilled the following selection criteria:
written informed consent; serum iPTH levels between
250 and 600 pg/ml in the 24 hours before the trans-
plantation; panel of preformed antibodies <20% in the
24 hours before the transplantation or considered by
the investigator to be a low immunological risk; serum
calcium (corrected for albumin) <10 mg/dl in the 24
hours before the transplantation; and receiving stan-
dard immunosuppressive treatment with basiliximab,
tacrolimus, mycophenolate mofetil, or mycophenolic
acid and steroids. No change in the immunosuppressive
regimen was allowed throughout the whole study
period. Main exclusion criteria were >1 previous
kidney transplantation, positive crossmatch, ABO
incompatible transplantation, patients who received
cinacalcet 48 hours before transplantation, and patients
with any active viral infection. Use of cinacalcet,
biphosphonates, and/or any type of vitamin D apart
from the study medication was not allowed during the
study. Women of child-bearing potential were tested
for pregnancy at screening visit and were informed to
avoid pregnancy during the study. Patients who did
not meet inclusion and/or exclusion criteria after the
screening period were considered to be a screening
failure and were not included in the statistical analysis.
Study Groups
An algorithm was used to generate random numbers by
computer for a simple randomization; patients who
satisfied the inclusion and/or exclusion criteria were
assigned sequentially at a 1:1 ratio to the PAR or the
CAL group. The PAR group was treated with oral PAR
(Zemplar, Abbvie Inc., North Chicago, Illinois). The
starting dose of PAR was 1 mg/d, but this dose could be
adjusted based on the serum iPTH and serum calcium
levels (Supplementary Figure S1). Briefly, the PAR dose
was increased to 2 mg/d if iPTH was >110 pg/ml and123
CLINICAL RESEARCH JM Cruzado et al.: Vitamin D and Transplantationcalcium was #10 mg/dl. PAR dose was reduced to 1 mg
every other day if iPTH was #110 pg/ml and calcium
was >10.3 mg/dl. PAR was discontinued if calcium
was >10.3 mg/dl and iPTH was >110 pg/ml.
The CAL group was treated with oral CAL (Hidroferol,
FAES Farma, Madrid, Spain). The starting dose was
5 drops/d (20 mg or 1200 IU), and the maintenance dose
was adjusted based on the 25(OH)D levels
(Supplementary Figure S2). Study medication was
started in the first 7 days post-transplantation as soon
as the patient satisfied the eligibility criteria and was
continued up to 6 months post-transplantation. Dose
adjustments of the study medications were performed
at months 1 and 3. During the randomization process,
patients were stratified based on if the patient was a
first-time recipient of a kidney or if the patient had
already had a previous kidney transplantation.
Primary and Secondary Efficacy Endpoints
The primary outcome of this study was to demonstrate
the superiority of PAR treatment at early renal
post-transplantation in the control of iPTH (percentage
of patients with serum iPTH >110 pg/ml at 6 months)
compared with the use of CAL. Secondary objectives
were changes on bone turnover biomarkers and BMD,
the effect on recipient alloimmune response (clinical
and subclinical acute rejection, de novo donor-specific
antibodies, parameters of renal function, blood pres-
sure and pulse-wave velocity, and acute (subclinical
rejection and borderline changes) and chronic (inter-
stitial fibrosis and tubular atrophy [IFTA]) allograft
damage and calcification (in hematoxylin and eosin
stained samples) in the 6-month protocol biopsy. The
assessment of serum iPTH, CAL, calcium, phosphorus,
FGF23, and bone turnover biomarkers was performed
in a central laboratory. A pathologist who was unaware
of study groups diagnosed protocol biopsies. From a
safety point of view, the frequency of adverse events
related to treatment with PAR and CAL, and the inci-
dence of adverse effects that required treatment
discontinuation between the 2 arms were evaluated.
Statistical Analyses
Continuous variables with normal or symmetrical dis-
tribution were reported as mean  SDs. The categorical
variables were described with frequencies and per-
centages. The differences between the 2 groups for
continuous variables were analyzed using Student’s t
test or the Wilcoxon rank-sum test, as appropriate. The
differences between categorical variables were
analyzed using the c2 distribution and Fisher exact
test, as appropriate. All statistical tests were considered
significant if the P value was <0.05 for 2-tailed tests.
The primary efficacy variable was analyzed using the124intention-to-treat (ITT) and per-protocol approach.
Statistical analysis was performed with the SAS
program (SAS Institute, Cary, North Carolina). All
safety analyses were conducted on the ITT data sheet
using the MedRA code and classifying them as an
adverse event or serious adverse event.
The study sample size was calculated based on
previous publications on the effect of PAR on bone
mineral metabolism in stage 3 and 4 CKD patients. It
was assumed that the difference between the arm
treated with PAR versus the arm treated with CAL in
the proportion of patients with iPTH >110 pg/ml
would be 20%. It was expected that the percentage of
patients treated with PAR compared with those who
received CAL with iPTH >110 pg/ml would be 20%
and 40%, respectively. Based on this assumption and
using the Fisher exact test with a 2-tailed significance
level of 0.05 and a power of 80%, the sample size
would be 90 patients per treatment group, for a total of
180 patients. The planned recruitment period was 12
months (between January 2014 and December 2014)
and then extended until February 2015 due to the low
recruitment rate. Recruitment was stopped on February
2015, after including 148 screened patients. The reason




Of 148 screened participants, 48 patients were excluded
because they did not fulfill the inclusion criteria, 2
patients decided not to participate in the study, and
4 patients were excluded for other reasons. Thus,
94 participants were randomized: 46 patients to PAR
and 48 patients to CAL (Figure 1). One patient was not
included in the ITT analysis because this patient did not
receive study medication due to protocol deviation
related to the inclusion criteria. Baseline characteristics
of the 2 groups were similar (Table 1). The initial PAR
dose was 1 mg/d. At 3 months, PAR doses were as
follows: 1 mg/d (50%); 1 mg/48 hours (8.7%); 2 mg/d
(39.1%); and discontinued in 2.2%. At 6 months, PAR
doses were as follows: 1 mg/d (60.9%); 1 mg/48 h (8.7%);
2 mg/d (21.7%); and discontinued in 8.7%. The CAL
starting dose was 5 drops/d. At 3 months, CAL doses
were changed as follows: 5 drops/d (36.2%); 7 drops/d
(61.7%); and discontinued in 2.1%. At 6 months, doses
were 5 drops/d (80.9%), 7 drops/d (14.9%), and 4.2%
discontinued (Table 2).
Primary Efficacy Analysis
If not specified, all the comparisons were performed on
the ITT population. The number of patients with serum
iPTH levels >110 pg/ml at 6 months of follow-up wasKidney International Reports (2018) 3, 122–132
Enrollment Assessed for eligibility (n = 148)
Excluded* (n = 54)
- Not meeting inclusion criteria (n = 48)
- Declined to participate (n = 2)
- Other reasons (n = 4)
Randomized (n = 94)
Allocated to paricalcitol 1 µg/d (n = 46)
- Received allocated medication (n = 46)
- Did not receive allocated medication (n = 0)
Allocation
Follow-up
End study (n = 37)
Withdrawal (n = 9)
- Physician’s decision (n = 1)
- Lack of response (n = 3)
- Withdrawal due to AE (n = 4)
- Screening failure (hepatitis) (n = 1)
End study (n = 41)
Withdrawal (n = 6)
- Physician’s decision (n = 1)
- Withdrawal due to AE (n = 3)
- Patient’s decision (n = 2)
Analysis 
ITT population (n = 46)
PPC population (n = 29)
Allocated to calcifediol 5 drops/d (n = 48)
- Received allocated medication (n = 47)
- Did not receive allocated medication (n = 1) because 
patient was not eligible due to Timoglobuline 
concomitant treatment (78-05) 
ITT population (n = 47)
PPC population (n = 35)
Figure 1. CONSORT flow diagram of the study population. The intention-to-treat population (ITT) was defined as randomized patients who took
at least 1 dose of study medication. The per-protocol (PPC) population was defined as the ITT patients who fulfilled the medication algorithm
without major protocol deviations. There were 112 protocol deviations (1 related to selection criteria, 50 related to procedures, and 4 related to
forbidden medication). AE, adverse event.
JM Cruzado et al.: Vitamin D and Transplantation CLINICAL RESEARCHlower in the group treated with PAR, but this was not
statistically significant (9 patients vs. 17 patients;
19.6% vs. 36.2%; P ¼ 0.07). However, when analyzing
the per-protocol population, a statistically significant
result was observed (2 patients vs.12 patients; 6.9% vs.
34.3%; P ¼ 0.008). We also observed that serum iPTH
levels were significantly lower in patients who received
PAR (76  55 pg/ml vs.101  55 pg/ml; P ¼ 0.0036) at
6 months of follow-up (Figure 2a and Table 2). No
significant difference was observed between the groups
in the proportion of patients with a reduction in serum
iPTH levels of $30% (95.1% vs. 88.4% in PAR and
CAL groups, respectively; P ¼ 0.26). The proportion of
patients with iPTH between 70 and 110 pg/ml was
14.6% in the PAR group and 25.6% in the CAL group
(P ¼ 0.056). As shown in Figure 2b, there was a
Kidney International Reports (2018) 3, 122–132significantly higher proportion of patients in the PAR
group with iPTH <70 pg/ml (63.4% vs. 37.2%;
P ¼ 0.028).
Effect on Mineral and Bone Disorder Outcomes
All bone turnover biomarkers (osteocalcin, bone alkaline
phosphatase, and C-terminal telopeptide) significantly
decreased at month 6 in comparison to baseline (Table 2),
without significant differences between groups. FGF23
also decreased in both treatment groups, although, at
6 months of follow-up, FGF23 values were lower in
patients treated with CAL. Femoral neck and lumbar
spine BMD, as assessedbydual-energyx-ray absorption,
showed no significant differences between treatments.
Similar BMD results were observed when the per-
protocol population was analyzed (data not shown).125







(n [ 47) P value
Age (yr) 57.5  13.8 58.9  13.0 56.2  14.5 0.38
Sex (M/F) 63/30 32/14 31/16 0.71
Caucasian, n (%) 87 (93.5) 44 (95.7) 43 (91.5) 0.36
BMI (kg/m2) 26.6  4.6 26.9  4.8 26.3  4.4 0.56
Cause of ESRD
Diabetes 12 6 6
Hypertension 5 1 4
Glomerulonephritis 21 13 8
APKD 9 2 7
Unknown 26 15 11
Other 20 9 11 0.34
Previous transplant
(yes/no)
6/87 3/43 3/44 1.00
Pretransplant PRA (%) 1.0  4.2 1.5  5.7 0.4  1.4 0.97
Donor type (live/
deceased)
20/73 9/37 11/36 0.65
Donor age (yr) 59.1  15.9 61.3  15.2 56.9  16.4 0.25
Donor sex (M/F) 44/49 21/25 23/24 0.60
HLA DR match (0/1/2) 14/40/39 7/22/17 7/18/22 0.60
APKD, adult polycystic kidney disease; BMI, body mass index; ESRD, end-stage renal
disease; HLA, human leukocyte antigen; HLA-DR, human leukocyte antigen–antigen-D
related; PRA, panel reactive antibodies.
CLINICAL RESEARCH JM Cruzado et al.: Vitamin D and TransplantationOther Secondary and Exploratory Outcomes
Overall, acute rejection was diagnosed in 7 patients
(7.5%). Incidence of acute rejection was 10.9% and
4.3% in the PAR and CAL groups, respectively
(P ¼ 0.23). Incidence of delayed graft function wasTable 2. Evolution of serum calcium, phosphate, iPTH, biomarkers of bon
Measurement
Paricalcitol
Baseline Month 3 Mo
iPTH (pg/ml) 338  135 83  50a,b 76 
FGF23 (pg/ml) 633 (102; 19,468) — 157 (37
Calcium (mg/dl) 8.89  0.62 9.58  0.6a 9.69
Phosphorus (mg/dl) 4.27  1.36 3.25  0.7a 3.42
25(OH)D3 (ng/ml) 18.7  11.2 —
Dosing (%) 2 mg/d (39.1)
1 mg/d (50)







C-terminal telopeptide (ng/ml) 1.33  0.75 — 0.44 
Bone formation biomarkers
Alkaline phosphatase (UI/l) 13.8  6.9 — 11.7
Osteocalcin (UI/l) 11.7  9.2 — 4.0 
Renal function
eGFR (ml/min) — 40  19 43
Albuminuria (mg/g) — 103  164 59 
Bone mineral density
Femoral neck (T-score) 1.05 (1.5) — 1.1
Lumbar spine (T-score) 0.64 (1.8) — 0.4
Pulse-wave velocity
PWV (m/s) 8.8  3.2 9.4
PWV <10 m/s 75% 64
eGFR, estimated glomerular filtration rate; FGF23, fibroblast growth factor-23; iPTH, intact para
The FGF23 results are reported and analyzed as median (minimum, maximum).
aP < 0.05 value versus baseline value.
bP < 0.05 calcifediol versus paricalcitol.
cP < 0.10 calcifediol versus paricalcitol.
12611.8% (17.4% in the PAR group and 6.4% in the CAL
group; P ¼ 0.12).
GFR was estimated by Chronic Kidney Disease
Epidemiology Collaboration. Both study groups
showed a similar eGFR at 1 month. However, eGFR at 3
and 6 months was significantly higher in the CAL
group than in the PAR group (Figure 3a). Furthermore,
at 6 months, the percentage of patients with eGFR
<30 ml/min per 1.73 m2 was 26.9% and 13.9% in the
PAR and CAL groups, respectively (P ¼ 0.18). Like-
wise, eGFR $60 ml/min per 1.73 m2 was 14.6% in the
PAR group and 27.9% in the CAL group (P ¼ 0.18)
(Figure 3b). In contrast, no significant differences
between treatments were observed for albuminuria
(Table 2) or proteinuria (data not shown).
Six-month protocol biopsies were performed in 36
patients (17 treated with PAR and 19 treated with
CAL). Protocol biopsies were not performed if the
patients had allograft failure (n ¼ 2), medical and
technical contraindications (n ¼ 10), medical decisions
(n ¼ 15), and decisions by the patients (n ¼ 30). There
were no differences with regard to subclinical acute
rejection and borderline changes. However, the pres-
ence of IFTA tended to be higher in the PAR group
than in the CAL group (Figure 4). Tubulointerstitial
calcifications in protocol biopsies were seldom found
(only 1 patient in the PAR group). Of 93 analyzede turnover and renal function
Calcifediol
nth 6 Baseline Month 3 Month 6
55a,b 315  118 99  39a,b 101  55a,b
; 46,314)a 607 (37; 23,241) — 101 (37; 6208)a,c
 0.5a 8.93  0.64 9.52  0.5a 9.57  0.5a
 1.0a 4.15  1.12 3.04  0.5a,c 3.10  0.6a











0.30a 1.29  0.60 — 0.56  0.30a
 9.1a 14.5  7.4 — 11.8  5.1a
3.6a 12.6  8.5 — 5.2  4.1a
 19 — 49  18c 52  21c
111 — 51  52 48  61
3 (1.7) 1.28 (1.3) — 1.25 (1.3)
7 (1.8) 0.45 (1.9) — 0.77 (1.8)
 2.8 8.7  2.5 9.3  3.9
.7% 68.2% 70.6%
thyroid hormone; PWV, pulse-wave velocity.






































Figure 2. Serum intact parathyroid hormone (iPTH) levels and iPTH distribution at 6 months. (a) Both paricalcitol (PAR) and calcifediol (CAL)
treatments were associated with significant reduction of serum iPTH mean values at 1, 3, and 6 months after transplantation. Serum iPTH mean
levels were lower in the PAR group than in the CAL group (P ¼ 0.009). (b) iPTH mean values distribution at 6 months after transplantation was
different between the PAR and CAL groups. The percentage of serum iPTH<70 pg/mlwas higher in the PAR group than in the CAL group (P¼ 0.028).





















Figure 3. Estimated glomerular filtration rate (eGFR) evolution and
stage of chronic disease distribution at 6 months after trans-
plantation. (a) Estimated Chronic Kidney Disease Epidemiology
Collaboration eGFR at 3 and 6 months after transplantation was
significantly lower in the paricalcitol (PAR) group than in the cal-
cifediol (CAL) group. (b) eGFR distribution according CKD stages at 6
months after transplantation. The percentage of patients with
eGFR $60 ml/min per 1.73 m2 was nearly double that in the CAL
group than in the PAR group.
JM Cruzado et al.: Vitamin D and Transplantation CLINICAL RESEARCHpatients, 82 were tested to detect the presence of anti-
human leukocyte antigen antibodies at the moment of
transplantation and at month 6. Ten patients showed a
positive result at transplantation, 5 in each
study group, but only 1 in the CAL group had a
donor-specific antibody. At 6 months of follow-up, 2
patients (1 in each study arm) developed de novo
donor-specific antibodies.
Hypertension was evaluated by 24-hour ambulatory
blood pressure at baseline and at 6 months. Baseline
results were similar in both study groups. Daytime
systolic blood pressure at 6 months was 132  15 and
136  16 mm Hg in the PAR and CAL groups,
respectively (P ¼ 0.29). Daytime diastolic blood pres-
sure at 6 months was 79  11 and 78  10 mm Hg in
the PAR and CAL groups, respectively (P ¼ 0.62). At
nighttime, similar results were observed between
treatments (systolic blood pressure was 117  41 and
129  27 mm Hg; P ¼ 0.20, and diastolic blood pres-
sure was 67  25 and 72  15 mm Hg; P ¼ 0.89; in the
PAR and CAL groups, respectively). Similarly, no
significant differences in the pulse-wave velocity were
observed between treatments (Table 2). Use of renin-
angiotensin system blockade was 13% and 14.9% in
the PAR and CAL groups, respectively.
Safety
All patients were alive at the end of the study. Two
patients lost their grafts, both in the CAL group
(primary nonfunction and surgical-related complica-
tion). Of 93 analyzed patients, 79 (84.9%) had at least
1 adverse event, 41 in the PAR group and 38 in the
CAL group (89.1% vs. 80.9%; P ¼ 0.26). Most side
effects were nonserious (261 of 328) in both arms, and
only 3 events were considered possibly or probably
related to the study drug (2 in the PAR group and 1 inKidney International Reports (2018) 3, 122–132the CAL group). Sixty-seven serious adverse events
were reported in 44 patients (Table 3), 37 in 24 par-
ticipants who received PAR and 30 in 20 patients who
received CAL (52.2% vs. 42.6%; P ¼ 0.35). No serious












Figure 4. Histological findings in 6-month protocol biopsies. No
differences were observed regarding inflammation categories
(subclinical rejection [ScR] [5.6%] and borderline changes [BLc]
[28.3%]). Overall, interstitial fibrosis and tubular atrophy (IFTA) was
diagnosed in 37% of protocol biopsies. However, this diagnosis was
nearly double in the paricalcitol (PAR) group than in the calcifediol
(CAL) group (48% vs. 23.8%; P ¼ 0.09).








Patients who reported at least 1
adverse event
P ¼ 0.26 (c2)
41 (89.1) 38 (80.9) 79 (84.9)
Patients who reported an adverse
event possibly or probably
related to the study drug
P ¼ 0.62 (c2)
2 (4.3) 1 (2.1) 3 (3.2)
Patients who had serious adverse
events
P ¼ 0.35 (c2)
24 (52.2) 20 (42.6) 44 (47.3)
Patients who reported a serious
adverse event possibly or
probably related to the
study drug
0 (0.0) 0 (0.0) 0 (0.0)
Patients who were withdrawn due
to an adverse event
P ¼ 0.68 (Fisher)
2 (4.3) 4 (8.5) 6 (6.5)
Patients who reported moderate or
severe adverse events
P ¼ 0.14 (c2)
34 (73.9) 28 (59.6) 62 (66.7)
Values are n (%).
CLINICAL RESEARCH JM Cruzado et al.: Vitamin D and Transplantationtract infection, renal impairment, and diarrhea were
the most commonly reported adverse events in 23.7%,
15.1%, and 11.8% of patients, respectively. Cyto-
megalovirus infection was 4.3% in each study group.
Overall, hypercalcemia, defined as serum calcium
>10.3 mg/dl, was reported in 7.1% and 4.7% in the
PAR and CAL groups, respectively (P ¼ 0.67).
Hypercalcemia that caused dose adjustment of study
medications was numerically higher in the PAR
group. At month 1, hypercalcemia was observed
in 7% and 2.2% in the PAR and CAL groups,
respectively (P ¼ 0.35). At month 3, hypercalcemia
was observed in 12.2% and 4.4% in the PAR and CAL
groups, respectively (P ¼ 0.19).
DISCUSSION
Among the CKD population, CKD-MBD is common and
becomes even worse after kidney transplantation.
There is a significant bone loss in the first year after
transplantation, followed by mild improvement there-
after.22,23 In addition to pretransplantation pathogenic
mechanisms, immunosuppression and vitamin D defi-
ciency may account for impaired bone formation and
mineralization in this setting. The Kidney Disease
Improving Global Outcomes guidelines recommend
vitamin D replenishment as first-line therapy in SHPT
when calcidiol is <30 ng/ml. Surprisingly, most studies
are observational, and interventional studies are scarce.
Moreover, the natural history of PTH after trans-
plantation is that PTH will decrease in many patients
during the first 6 to 12 months,11 which is associated
with recovery of renal function and could be a
confounding factor in clinical trials. To minimize this
effect and in contrast with the study by Amer et al.,20
we decided to include only patients with clinically128significant SHPT before transplantation (iPTH 250600
pg/ml). Wolf et al.24 demonstrated that patients with
pretransplantation iPTH >300 pg/ml had iPTH levels
at 6 months that were approximately 200 pg/ml, and
persistent SHPT (defined as PTH >65 pg/ml) was
observed in >90% of these patients. Thus, the
achievement of iPTH normalization at 6 months in the
patients enrolled in the paridoinal study was unlikely
done without treatment.
Our study was the first one to compare the use of
PAR with nutritional vitamin D replenishment in de
novo renal allograft recipients with SHPT before
transplantation. We found that, although PAR
seemed more effective than CAL to reduce iPTH, it
was associated with a higher risk of iPTH <70 pg/ml.
Although the ideal iPTH level after kidney trans-
plantation is unknown and probably will depend on
the GFR achieved, our results suggested that PAR,
rather than CAL, might exacerbate adynamic bone
disease. Finding that controlled PTH production was
associated with reduced serum levels of biomarkers of
bone formation (e.g., osteocalcin and bone alkaline
phosphatase) and at the same time, reduced
biomarker of osteoclastic-mediated bone reabsorption
(e.g., C-terminal telopeptide)25 provided consistent
evidence that both therapies might effectively
suppress the high-turnover bone disease that char-
acterizes SHPT. This also suggested that, in the long
term, vitamin D replenishment and PAR could help to
prevent progressive bone mass loss and excess risk of
pathological bone fractures that are invariably asso-
ciated with SHPT, particularly in recipients of kidney
transplantations.26,27 However, because osteocalcin
and C-terminal telopeptide are renally cleared, theKidney International Reports (2018) 3, 122–132
JM Cruzado et al.: Vitamin D and Transplantation CLINICAL RESEARCHreduction in their levels, rather than changes on bone
mineral turnover, might merely be related to the
recovery of renal function achieved after kidney
transplantation.28 Despite the observation on bone
biomarkers and in agreement with previous studies,
we observed bone loss during the first 6 months after
transplantation in both study groups. This finding
could be mainly related to immunosuppression,
which was homogenous per protocol and consistent
with the current standard of care. Amer et al.20
compared PAR versus placebo in incident renal
allograft recipients regardless of the pre-
transplantation iPTH level. They found PAR was able
to reduce iPTH but also without benefits in BMD. In
contrast, Trillini et al.21, in prevalent kidney trans-
plantation with SHPT, showed that PAR versus
non-PAR therapy was associated with iPTH reduction
and lumbar BMD improvement. There was a previous
study that demonstrated that calcium plus calcitriol
attenuated BMD changes at 1 year.29 The ongoing
VITALE (Vitamin D Supplementation in Renal
Transplant Recipients) study30 is comparing a high
dose of cholecalciferol versus a low dose of chole-
calciferol in prevalent kidney allograft recipients
with vitamin D deficiency. Although the primary
endpoint explored vitamin D pleiotropic effects,
there was a secondary endpoint to assess changes in
BMD and bone fractures at 2 years. Further studies
with more prolonged follow-up are required to assess
the effects of both PAR and vitamin D replenishment
on BMD and bone fractures.
FGF23 and PTH regulate each other in a negative
feedback loop, in which PTH stimulates FGF23 syn-
thesis and FGF23 suppresses iPTH production action
by the Klotho-FGFR1 complex in the parathyroid
gland.1,31 However, in CKD, reduced Klotho accounts
for high iPTH despite elevated FGF23. After trans-
plantation, FGF23 levels can remain elevated for
months despite restored renal function, and, in com-
bination with high iPTH, these levels might contribute
to inappropriately low levels of calcidiol.1 High levels
of FGF23 have been associated with endothelial
dysfunction, volume overload, and an increased risk of
cardiovascular mortality.1,11,31 In our study, the
reduction of FGF23 seemed higher in the CAL group
than in the PAR group. Experimental data suggest that
VRDAs could increase FGF23. Recently, Donate-Correa
et al.31 found that PAR treatment in prevalent kidney
transplants with SHPT was associated with an
increased Klotho, reduced iPTH, and increased FGF23.
However, more studies are needed to investigate
whether PAR and vitamin D replenishment induce
different effects on the imbalanced FGF23-PTH-vitamin
D axis.Kidney International Reports (2018) 3, 122–132We also investigated some of the pleiotropic effects
attributed to PAR.32 In particular, we monitored
immune response in a homogenous cohort that
received basiliximab induction therapy, tacrolimus,
mycophenolate, and prednisone immunosuppression.
The incidence of both clinical and subclinical acute
rejection was low, in line with the results achieved
with current immunosuppression in the low immu-
nological risk population.33 There were no differences
between PAR and CAL regarding rejection and de
novo donor-specific antibody development. These
findings suggested that PAR, in comparison with
nutritional vitamin D replenishment, was not associ-
ated with a higher prevention of immunologically
mediated allograft damage.
We found that PAR treatment was associated with
lower GFR than CAL, whereas proteinuria levels were
similar. Although unexpected, these results were
consistent with a previous study carried out in preva-
lent renal transplant recipients with SHPT. Trillini
et al.21 suggested that decreased creatinine tubular
secretion, increased creatinine generation, or both,
could explain this finding because VDRAs did not affect
inulin clearance, which is the gold standard for
measuring GFR. However, in agreement with a lower
eGFR, we also found a higher proportion of chronic
renal allograft lesions (IFTA) in 6-month protocol
biopsies in patients treated with PAR. This finding was
an apparent discrepancy with a previous study that
compared PAR versus placebo, in which PAR was
associated with reduced moderate IFTA in protocol
biopsies.20 Because our study was the first to compare
PAR with vitamin D replenishment and took previous
studies into account, our results suggested that the
observed differences in kidney function and renal
damage might rely on the beneficial effect of vitamin D
replenishment rather that on the nephrotoxicity of PAR.
It was reported that vitamin D downregulated renin
expression, transforming growth factor b1 and tubu-
lointerestitial fibrosis in animal models of kidney
damage.34 This effect could be particularly relevant in
our cohort of patients with a high proportion of trans-
planted kidneys from older donors. The ongoing VITA-
D (the cholecalciferol substitution in vitamin D deficient
kidney transplant recipients) study will provide further
information regarding the immunomodulatory and
renoprotective effects of cholecalciferol in renal allograft
recipients with vitamin D deficiency.35 In contrast,
tubulointerstitial calcifications in protocol biopsies were
rare and only observed in 1 patient treated with PAR.
Thus, renal calcification did not seem to be associated
with the eGFR differences between groups.
The cause of posttransplantation proteinuria could
be multifactorial, including immunological and129
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that PAR reduces albuminuria in kidney trans-
plantations, although the mechanism accounting for
this effect is not clear.21 Nevertheless, Amer et al.20
reported similar proteinuria in a clinical trial that
compared PAR versus placebo in incident renal allo-
graft recipients. Our results were concordant with this
study and showed that PAR and vitamin D replenish-
ment had a similar effect on the level of proteinuria and
albuminuria observed after transplantation.
In CKD patients, vitamin D is considered protective
against cardiovascular disease (CVD).1,32 Vitamin D is
an endocrine suppressor of the renin-angiotensin-
aldosterone system.36 Although CVD is the main
cause of mortality in renal transplantation, few studies
have reported an association between vitamin D defi-
ciency and mortality in this population.1 In this regard,
the short-term follow-up in our study was a limitation
to assess CVD. To estimate cardiovascular risk, we
measured changes in arterial stiffness and blood pres-
sure. Experimental studies suggested that PAR is
superior to doxercalciferol to prevent vascular calcifi-
cation and arterial stiffness in uremic rats.37 Lundwall
et al.38 found that PAR was able to reduce pulse-wave
velocity and to ameliorate endothelial dysfunction in
CKD patients. These results were not confirmed in our
study because we found similar blood pressure and
arterial stiffness in patients treated with PAR and CAL.
Overall, treatment was well tolerated with few
episodes of hypercalcemia. Despite a slight trend to
more serious and nonserious adverse events with
PAR therapy, all treatment-related adverse events
were nonserious and generally mild; patients fully
recovered after treatment withdrawal. Our study had
some limitations and strengths. Limitations were
sample size because the enrollment goal was not
achieved, short-term follow-up, absence of 25(OH)D3
assessment in the PAR group, and lack of preim-
plantation renal biopsies. Some of these limitations
were caused by budget constraint related to the
academic nature of the study. Regarding 25(OH)D3, it
seems likely that, without supplementation, the cal-
cidiol levels remained low, as demonstrated by Per-
rin et al.39 Nevertheless, this was the first clinical
trial that compared PAR with CAL in de novo
kidney allograft recipients with a clinically relevant
degree of SHPT before transplantation. Major
strengths were study design, a homogeneous and
representative kidney transplant population with
pretransplantation SHPT, homogeneous immuno-
suppression, protocol biopsies, and assessment of
donor-specific antibodies.
In conclusion, in de novo kidney transplantation
recipients with SHPT, both PAR and vitamin D130replenishment reduced iPTH at 6 months after trans-
plantation. However, PAR treatment was associated
with a higher proportion of patients with iPTH <70
pg/ml, higher FGF23, lower eGFR, and more IFTA in
6-month protocol biopsies. Although these results
should be interpreted with caution due to statistical
power limitation, they did not support the use of PAR
to treat posttransplantation hyperparathyroidism.
Long-term controlled clinical trials are needed to
corroborate our short-term findings.DISCLOSURE
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SUPPLEMENTARY MATERIAL
Figure S1. Paricalcitol dose-adjustment algorithm. The
starting doseof Paricalcitolwas 1 mg/d. Paricalcitol dosewas
increased to 2 mg/d if iPTH> 110pg/ml and calcium# 10mg/
dl. Paricalcitol dose was reduced to 1 mg every other day if
iPTH# 110 pg/ml and calcium> 10.3mg/dl. Paricalcitol was
discontinued if calcium > 10.3 mg/dl and iPTH > 110 pg/ml.
Figure S2. Calcifediol dose-adjustment algorithm. The
starting dose was 5 drops (20 mg or 1200 IU)/d and the
maintenance dose was adjusted based on the 25(OH)D
levels.
Consortium Checklist. CONSORT 2010 checklist of
information to include when reporting a randomized trial.
Supplementary material is linked to the online version of
the paper at www.kireports.org.
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